Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 420-428

  Sorensen K D ^a   Abildgaard, M O ^a   Haldrup, C ^a   Ulhoi B P ^a   Kristensen, H ^a   Strand, S ^a   Parker, C ^b   Hoyer S ^a   Borre, M ^a   Orntoft T F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ANPEP; Biomarker; DNA methylation; Prognosis; Prostate cancer; Tissue microarray

Indexed keywords

COMPLEMENTARY DNA; MICROSOMAL AMINOPEPTIDASE;

ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METHYLATION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD13; AZACITIDINE; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84873566705     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.549     Document Type: Article

References (36)

1. Abildgaard MO, Borre M, Mortensen MM, Ulhøi BP, Tørring N, Wild P, Kristensen H, Mansilla F, Ottosen PD, Dyrskjøt L, Ørntoft TF, Sørensen KD (2012) Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. Int J Cancer 130(4): 885-895.
2. Bogenrieder T, Finstad CL, Freeman RH, PapandreoüCN, Scher HI, Albino AP, Reuter VE, Nanus DM (1997) Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 33(4): 225-232. (Pubitemid 27524700)
3. Borre M, Nerstrøm B, Overgaard J (1997) The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 80(5): 917-928. (Pubitemid 27360474)
4. Borre M, Nerstrøm B, Overgaard J (2000) Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGFexpressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6(5): 1882-1890. (Pubitemid 30305085)
5. Borre M, Offersen BV, Nerstrøm B, Overgaard J (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78(7): 940-944. (Pubitemid 28430025)
6. Boxler S, Djonov V, Kessler TM, Hlushchuk R, Bachmann LM, Held U, Markwalder R, Thalmann GN (2010) Matrix metalloproteinases and angiogenic factors: Predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol 177(5): 2216-2224.
7. Carl-McGrath S, Lendeckel U, Ebert M, Rocken C (2006) Ectopeptidases in tumour biology: A review. Histol Histopathol 21(12): 1339-1353. (Pubitemid 44614516)
8. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, LiüAY (2007) Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 7: 3.
9. Epstein JI, Allsbrook Jr. WC, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9): 1228-1242. (Pubitemid 41232997)
10. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2009) Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 69(11): 4708-4715.
11. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA, Stratford IJ (2007) Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67(1): 84-90. (Pubitemid 44959508)
12. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M (2002) Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 122(2): 376-386. (Pubitemid 34116989)
13. Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, Ørntoft TF, Tørring N (2008) SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 23(9): 1069-1076.
14. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M (2003) Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9(4): 1503-1508. (Pubitemid 36418408)
15. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, TatematsüM, Yamamoto H, Hirano K (2001) Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 92(1): 49-54. (Pubitemid 32187031)
16. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E (2011) Isolation and in vitro expansion of human colonic stem cells. Nat Med 17(10): 1225-1227.
17. Kawamura J, Shimada Y, Kitaichi H, Komoto I, Hashimoto Y, Kaganoi J, Miyake M, Yamasaki S, Kondo K, Imamura M (2007) Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. Hepatogastroenterology 54(73): 36-40. (Pubitemid 46511642)
18. Larkin SE, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, Harris S, Garbis SD, Townsend PA, Aukim-Hastie C (2012) Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer 106(1): 157-165.
19. LiüAY, Roudier MP, True LD (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165(5): 1543-1556. (Pubitemid 39435154)
20. LiüP, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS (2006) Sexdetermining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66(8): 4011-4019.
21. Mawrin C, Wolke C, Haase D, Kruger S, Firsching R, Keilhoff G, Paulus W, Gutmann DH, Lal A, Lendeckel Ü(2010) Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. Brain Pathol 20(1): 200-210.
22. Menrad A, Speicher D, Wacker J, Herlyn M (1993) Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53(6): 1450-1455. (Pubitemid 23097131)
23. Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ, Clinton SK (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27(33): 5627-5633.
24. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M (2005) Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res 11(24 Pt 1): 8674-8679. (Pubitemid 43005916)
25. Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH (2007) CD13/APN regulates endothelial invasion and filopodia formation. Blood 110(1): 142-150. (Pubitemid 47026829)
26. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M (2007) Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 27(5B): 3651-3660. (Pubitemid 47607515)
27. Rocken C, Licht J, Roessner A, Carl-McGrath S (2005) Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin Pathol 58(10): 1069-1075. (Pubitemid 41416057)
28. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1): 27-36.
29. Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L (2009) Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 15(4): 1400-1410.
30. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J (2011) PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 71(15): 1668-1679.
31. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, NasüY, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H (2007) Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67(11): 5117-5125. (Pubitemid 46997247)
32. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 7: 140.
33. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhøffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Tørring N, Dyrskjøt L, Andersen CL, Ørntoft TF (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7(7): 1214-1224. (Pubitemid 352038268)
34. Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 12(13): 3971-3978. (Pubitemid 44078082)
35. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9(4): 342-351.
36. Wulfanger J, Schneider H, Wild P, Ikenberg K, Rodolfo M, Rivoltini L, Meyer S, Riemann D, Seliger B (2012) Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis 33(4): 781-790.